Latest headlines across the TrendMatrix universe. Sentiment-scored, tickered, deduped. Updated every 5 minutes.
Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest
US Government Website Quietly Used Alibaba’s Qwen AI Amid FBI Accusations of China Firm Imitating Anthropic: Report
Applied Digital Surges After Wells Fargo Names Stock a Top Pick With $50 Price Target
Firefly Landed a $100 Million NASA Contract This Month — Here's What Else Happened
Here's How Much $100 Invested In Mercury System 20 Years Ago Would Be Worth Today
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy'
FDA Approves Telix Pharmaceuticals Brain Cancer Imaging Drug
Viasat and SPACE42 Partner on $1 Billion ‘Equatys’ Direct-To-Device Satellite Venture
Compass CEO Warns Housing Market Is Splitting Apart as 42% of Homes See Price Cuts, Highest in Nearly a Decade: 'There's
Compass Pathways’ Psilocybin Treatment Shows Lasting Benefits in Treatment-Resistant Depression
ZWS Maintained by Oppenheimer -- Price Target Raised to $60 - GuruFocus
Leerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20
Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57
The FDA Grants Regenerative Medicine Advanced Therapy Designation to Autolus Therapeutics' Obecabtagene Autoleucel for S
Morgan Stanley Upgrades Flagstar Bank to Overweight, Raises Price Target to $17
Rigetti Computing Announces Definitive Agreement With Commerce Department For $100M CHIPS Act Award To Accelerate Superc
Cathie Wood Says AI Revolution Could Supercharge Global Growth — TSLA, COIN and CRSP Stocks Are Among Her Top Bets
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target